Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Business meeting

The ten-year, multi-million-pound fund will support social ventures created within the participating universities across the UK. The fund will support ventures motivated by beneficial social or environmental impact, rather than solely by profit.

Impact 12 has been developed by Social Investment Scotland (SIS), an impact investor and responsible finance provider based in Edinburgh, in partnership with the Universities of Oxford, Cambridge, Northampton, Coventry and eight universities comprising the MICRA Project (Aston, Birmingham, Cranfield, Keele, Leicester, Loughborough, Nottingham and Warwick). Oxford University Innovation leads the consortium.

Impact 12’s aim is to bring positive change, to people and places, by accelerating the development and success of impact-led social ventures spun out of universities. It will support social ventures with innovative finance tailored to their needs, including equity investment and debt. The fund will also provide access to timely and expert mission-aligned finance and impact support.

Read the full story on the Oxford University Innovation website

The story is also featured on the University of Oxford website

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.